The EPS miss and 66% revenue decline are clear negatives, but the Phase 3 ALLOHA-2 initiation and positive Phase 1 data provide a pipeline floor. Watch for Q4 2026 updates on Cohort C data and TSC-102 trials; the cash runway into Q2 2027 with debt amortization starting suggests a dilutive financing event is likely within 12 months. Short-term bearish on financials, but long-term value hinges on ALLOHA-2 readout in 2028.
Drug in focus
TCRX drug pipeline →TSC-101
▼ Bearish Named in this press release- Impact
- Phase
- Phase 3 (paused)
- Time to market
- Uncertain. The Phase 3 trial is paused due to insufficient capital, and the company is seeking a partner to continue development. Even if partnered, a pivotal trial would need to complete before any regulatory filing, putting potential approval years away.
- Next catalyst
- None dated
What to watchTSC-101's development is paused, and the stock's fate hinges entirely on whether TScan can secure a partnership for the heme program. Without a partner, the Phase 3 trial will not resume and the program may be abandoned. The company's focus has shifted to preclinical solid tumor candidates, which are years from clinical data. Monitor for partnership announcements or a potential sale of the heme assets.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 12 $0.7730entry
- T+1 · 3mo ago −0.13%α −0.83% · $0.7720
- T+5 · 3mo ago −2.98%α −2.53% · $0.7500
- T+20 · 2mo ago −58.87%α −56.98% · $0.3179
- T+60 · 12d ago −76.48%α −71.37% · $0.1818
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
TScan Therapeutics reported Q2 2026 EPS of -$0.23, a 15% miss vs consensus of -$0.20, and revenue of $1.1M, sharply down 66% YoY from $3.1M due to timing of Amgen collaboration activities. The net loss narrowed to $30.4M from $37.0M, but cash burn remains high with cash runway only into Q2 2027, pressured by upcoming debt amortization. Positive clinical data from the Phase 1 ALLOHA study and first patient dosed in the Phase 3 ALLOHA-2 trial provide pipeline catalysts, but the financial miss and cash constraints dominate the near-term outlook.
Key Financial Metrics
Key Facts
- Q2 2026 EPS -$0.23 vs consensus -$0.20 (15% miss)
- Q2 2026 revenue $1.1M, down 66% YoY from $3.1M
- Net loss $30.4M vs $37.0M YoY, but cash burn remains high
- Cash and equivalents $100.2M, runway only into Q2 2027
- Debt amortization begins Q4 2026 after milestone miss, pressuring cash
- First patient dosed in Phase 3 ALLOHA-2 trial; topline data expected mid-2028
- Positive initial data from Cohort C of Phase 1 ALLOHA study with 79% complete donor chimerism
- Pro forma shares outstanding 130.0M, significant dilution from pre-funded warrants
Financial Impact
EPS miss of $0.03 per share; revenue decline of $2.0M YoY; cash burn of ~$52M in H1 2026
Risk Factors
- Cash runway only into Q2 2027 with debt amortization starting Q4 2026, likely requiring dilutive financing
- Revenue heavily dependent on Amgen collaboration timing; no recurring revenue base
- Phase 3 ALLOHA-2 trial topline not expected until mid-2028, leaving long period of binary risk
- Significant dilution from 62.2M pre-funded warrants outstanding
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3343490 |
Track record
15 reports on TCRX
5 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +77.60% at T+60 after the Aug 18, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Bearish 7/10 Entry $0.1680 Now $0.1450 +13.69% settles Nov 19
- Oct 26, 202621d ago DEF 14A Bearish 6/10 Entry $0.1897 to $0.1745 Now $0.1450 +23.56% ▲ +8.01% +6.75% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $0.2102 to $0.1897 Now $0.1450 −31.02% ▼ −9.75% −9.61% vs SPY
- Sep 30, 20266w ago 8-K Neutral 2/10 Entry $0.3175 to $0.2282 Now $0.1450 −54.33% ▼ −28.13% −29.43% vs SPY
- Sep 25, 20267w ago SC 13G Neutral 3/10 Entry $0.3400 to $0.2953 Now $0.1450 −57.35% ▼ −13.15% −14.35% vs SPY
- Sep 11, 20269w ago 8-K Neutral 5/10 Entry $0.3204 to $0.3119 Now $0.1450 −54.74% ▼ −2.65% −2.43% vs SPY
- Sep 2, 202610w ago 8-K Bearish 7/10 Entry $0.3810 to $0.3179 Now $0.1450 +61.94% ▲ +16.56% +15.60% vs SPY
- Aug 18, 202612w ago 8-K Bearish 7/10 Entry $0.7500 to $0.7774 Now $0.1450 +80.67% ▼ −3.65% −4.04% vs SPY
- Aug 12, 202613w ago 8-K Bearish 6/10 No price data
- Aug 12, 202613w ago Press Release Bearish 6/10 Viewing Entry $0.7730 to $0.7500 Now $0.1450 +81.24% ▲ +2.98% +2.53% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers